Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorHunan Cancer Hospital
About this trial
This study aims to evaluate the efficacy of immunonutrition in reducing acute esophagitis after thoracic radiotherapy in lung cancer.
Eligibility criteria
Qualifiers
The subject voluntarily participates in this clinical study, understands the study procedures, and is able to provide written informed consent.
Age ≥ 18 years.
Pathologically confirmed diagnosis of lung cancer, including non-small cell lung cancer and small cell lung cancer.
Indication for thoracic radiotherapy, with the esophagus within 1 cm of the PTV.
Disqualifiers
Previous history of thoracic radiotherapy.
Suspected or confirmed tumor invasion of the esophagus.
Patients with other primary tumors.
History of esophageal cancer, gastric cancer, or prior esophageal surgery.
Trial design
Treatments tested in this trial
- Oral immunonutrition
Treatment groups
121 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov